Target intelligence / Profile preview

Glycosaminoglycan in nucleus pulposus

Molecular classification
Other
01

Overview

Glycosaminaminoglycans (GAGs) are large, negatively charged linear polysaccharides that are major components of the extracellular matrix in the nucleus pulposus, the central region of the intervertebral disc[1][2][4]. The main GAGs present include chondroitin sulfate, keratan sulfate, heparan sulfate, and hyaluronic acid, with aggrecan proteoglycan carrying many GAG chains. These molecules attract and retain water, conferring the high osmotic pressure necessary for the disc to resist compressive mechanical loads and maintain flexibility[1][4][5]. With degeneration, GAG synthesis decreases, resulting in loss of disc hydration, biomechanical dysfunction, and increased risk of lower back pain and intervertebral disc disease[2][5]. GAG content of nucleus pulposus is a clinical biomarker for disc degeneration, and MRI-based techniques are used for noninvasive assessment[5].

Other names
Glycosaminoglycans in intervertebral discNP GAGDisc GAGs
02

Mechanism of action

Enzymatic degradation of glycosaminoglycans reduces NP GAG content, thereby affecting disc mechanics[2][3]

03

Biological functions

Extracellular matrix formationWater retentionLoad resistanceCompression resistance
04

Disease associations

Degenerative disc diseaseLow back painIntervertebral disc degeneration
05

Safety considerations

Loss of GAGs with age or degeneration leads to disc dehydration and chronic pain.There are no typical pharmacological interventions directly targeting GAGs that raise safety concerns, but enzyme treatments to reduce GAGs would undermine disc mechanical function[2][3].
06

Interacting drugs

Chondroitinase ABC (research tool, not a therapeutic drug)
07

Biomarkers

Glycosaminoglycan content as measured by gagCEST MRI for disc degeneration[5]

Beyond the preview

Go deeper on Glycosaminoglycan in nucleus pulposus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glycosaminoglycan in nucleus pulposus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call